CARDIOPROTECTIVE EFFECT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONIST IN DOXORUBICIN MYOCARD TOXICITY
Doxorubicin (Dox) is a first line drug in neoplasia treatment. It is however cardiotoxic even in moderate dosages. High mortality of oncological patients from cardiomyopathic heart failure on Dox treament is a serious problem of oncology and cardiology. Among the cardiotoxicity factors of Dox are ac...
Saved in:
| Main Authors: | M. I. Popovich, L. M. Cheban, L. A. Taku, V. М. Ivanov, I. М. Popovich, M. V. Ivanov, V. А. Rotaru, L. S. Mikhalchan, V. A. Kobets |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2018-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review
by: Shang W, et al.
Published: (2025-07-01) -
Vitamin C as a Cardioprotective Agent Against Doxorubicin‐Induced Cardiotoxicity
by: Hamdi Nsairat, et al.
Published: (2025-08-01) -
Combined effects of metformin and coenzyme Q10 on doxorubicin-induced cardiotoxicity in male wistar rats
by: Faraz Mahdizadeh, et al.
Published: (2025-07-01) -
The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01) -
Biomarkers of chemotherapy-induced cardiotoxicity: toward precision prevention using extracellular vesicles
by: Brian B. Silver, et al.
Published: (2024-04-01)